Integrated Financial Results as on March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aspira Pathlab reported audited standalone results for FY2026 (year ended March 31, 2026). Revenue from operations grew 13.6% to ₹2,498.20 lakhs from ₹2,199.90 lakhs in FY2025. However, profit after tax collapsed to ₹5.13 lakhs from ₹207.26 lakhs in the previous year—a decline of over 97%. Q4 FY2026 recorded a net loss of ₹68.91 lakhs compared to a profit of ₹72.33 lakhs in Q4 FY2025. EPS dropped to ₹0.05 per share from ₹2.01 previously. The company acquired Om Pathology Laboratory in Surat (effective February 2026) and transferred its stake in Aspira DNA Diagnostics Gujarat LLP (effective June 2025). The auditor issued an unmodified opinion, and operating cash flow remained positive at ₹145.36 lakhs.
The stock may face pressure as the company reported a sharp 97%+ decline in annual profit despite modest revenue growth, indicating severe margin compression. The Q4 loss raises concerns about profitability sustainability, though the positive operating cash flow provides some comfort.